Intellectual Property India Publishes Patent Application for 'RNAI Agents For Inhibiting Expression Of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, And Methods Of Use' Filed by Arrowhead Pharmaceuticals, Inc.

MUMBAI, India, Nov. 21 -- Intellectual Property India has published a patent application (202517097008 A) filed by Arrowhead Pharmaceuticals, Inc., Pasadena, U.S.A., on Oct. 8, for 'rnai agents for inhibiting expression of complement factor b (cfb), pharmaceutical compositions thereof, and methods of use.'

Inventor(s) include Li, Xiaokai; Pei, Tao; Schienebeck, Casi; Wang, Yichen; Ding, Zhi-Ming; and Shekhtman, Grigoriy.

The application for the patent was published on Nov. 21, under issue no. 47/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB...